CapsulesClinical Overview
Pomalidomide Capsules (2mg) is a third-generation, highly potent immunomodulatory agent (IMiD) on the WHO Model List framework. It binds to cereblon with >10-fold higher affinity than lenalidomide, recruiting and degrading IKZF1/IKZF3 even in lenalidomide-refractory multiple myeloma clones, triggering enhanced myeloma apoptosis and T-cell co-stimulation. Indicated in combination with low-dose dexamethasone for patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 4 mg once daily on days 1 to 21 of repeated 28-day cycles with water, with or without food. Swallow whole. Mandate thromboprophylaxis and pregnancy prevention.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Severe neutropenia, fatigue, anemia, constipation, nausea, diarrhea, dyspnea, thrombocytopenia. Rare/Severe: Deep vein thrombosis, pulmonary embolism, severe teratogenicity, and interstitial lung disease.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Teratogenic lethal birth defects (strict REMS program). Black Box Warning: Venous thromboembolism; mandatory thromboprophylaxis. Avoid concurrent strong CYP1A2 inhibitors (ciprofloxacin) or reduce dose.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, oncological diagnosis, or chemotherapy protocol guidance. Cancer therapies require specialized administration under the direct supervision of a registered medical oncologist in an accredited healthcare facility.